ocrelizumab

MS Society protests NICE rejection of Ocrevus for primary progressive MS
BioCentury
Mon, 09/10/18 - 12:16 am
NICE
UK
MS
multiple sclerosis
Ocrevus
ocrelizumab
Roche
Roche granted approval for ocrelizumab (multiple sclerosis) in Europe
GoinPharma
Sat, 01/13/18 - 10:48 pm
Roche
ocrelizumab
Europe
MS
multiple sclerosis
Roche secures FDA approval for Ocrevus for two types of MS
BioPharma Dive
Tue, 03/28/17 - 11:56 pm
Roche
Ocrevus
FDA
ocrelizumab
MS
multiple sclerosis
Roche’s Multiple Sclerosis Drug Shows Positive Results in Several Clinical Trials
Xtalks
Fri, 01/13/17 - 11:20 am
Roche
MS
multiple sclerosis
ocrelizumab
clinical trials
Roche touts efficacy of MS drug despite delays
BioPharma Dive
Tue, 12/27/16 - 10:16 am
Roche
MS
multiple sclerosis
Ocrevus
ocrelizumab
FDA pushes decision on Roche MS drug to March
BioPharma Dive
Wed, 12/21/16 - 11:13 am
FDA
Roche
MS
multiple sclerosis
Ocrevus
ocrelizumab
Roche’s megablockbuster MS candidate ocrelizumab posts promising head-to-head data
Endpoints
Wed, 09/14/16 - 11:42 pm
Roche
MS
multiple sclerosis
ocrelizumab
You'll Never Guess Which Pharma Likely Owns 40% of 2016's New Blockbusters
Motley Fool
Sat, 03/19/16 - 02:41 pm
Roche
Genentech
ocrelizumab
atezolizumab
venetoclax
New rivals, formulary squeeze pose a double threat to Biogen MS sales
Fierce Pharma
Mon, 03/7/16 - 10:04 pm
Biogen
formulary
MS
multiple sclerosis
Roche
ocrelizumab
Tecfidera
New drug for severe form of MS generates glimmer of hope — and tempered expectations
Stat
Fri, 02/19/16 - 10:07 am
MS
multiple sclerosis
Roche
ocrelizumab
5 Reasons Roche Thinks It Can Outclass the Competition
Motley Fool
Fri, 11/13/15 - 04:23 pm
Roche
atezolizumab
ACE910
hemophilia A
lampalizumab
dry macular degeneration
ocrelizumab
Did Roche Unleash Biogen's Worst Nightmare?
Motley Fool
Tue, 10/20/15 - 05:55 pm
Roche
Biogen
MS
multiple sclerosis
ocrelizumab
Roche drug may set new benchmark in MS, data suggest
Yahoo/Reuters
Thu, 10/8/15 - 12:31 pm
Roche
multiple sclerosis
MS
ocrelizumab
Roche poised for MS coup with PhIII success in progressive disease
Fierce Pharma
Thu, 10/1/15 - 05:27 pm
MS
multiple sclerosis
Roche
ocrelizumab
Innovation Remains Best Remedy In Drug Pricing Debate
Forbes
Wed, 09/30/15 - 09:35 am
innovation
drug pricing
ocrelizumab
Roche
Roche preps for make-or-break MS data with eyes on a crowded space
Fierce Biotech
Thu, 09/17/15 - 05:19 pm
Roche
MS
multiple sclerosis
ocrelizumab
Roche's MS hopeful will amp up payer pricing pressure, analyst says
Fierce Pharma Marketing
Wed, 07/8/15 - 11:41 am
Roche
MS
multiple sclerosis
ocrelizumab
Roche heralds PhIII successes for MS, but some tough rivals lie in wait
Fierce Biotech
Tue, 06/30/15 - 10:43 am
Roche
multiple sclerosis
ocrelizumab
MS
The Top 10 Phase III Failures of 2010
Fierce Biotech
Fri, 10/22/10 - 11:36 am
clinical trials
dimebon
Medivation
Pfizer
ocrelizumab
Roche
rheumatoid arthritis
taspoglutide
diabetes
Ipsen
semagacestat
Eli Lilly
ASA404
Antisoma
Novartis
Novelos Therapeutics
AstraZeneca
zibotentan
vicriviroc
Merck
Recentin
Vical
Sanofi
A Potential Blockbuster Bites the Dust. Should You Worry?
Motley Fool
Wed, 05/19/10 - 06:08 pm
Biogen Idec
ocrelizumab
Roche
rheumatoid arthritis

Pages